Statistics
Publications
73
Citations
13.5K
H-Index
41
Active since
2002
Ryohei Katayama is an author at Japanese Foundation For Cancer Research specializing in oncology, molecular oncology, and medicine.
Publications per year
2002–2025
73
73
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou et al. · Journal of Clinical Oncology · 2012 · 1.6K citations · Full text
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama, Alice T. Shaw, Tahsin Khan et al. · Science Translational Medicine · 2012 · 1.3K citations
Medicine, Oncology, Pharmacology +17
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Luc Friboulet, Nanxin Li, Ryohei Katayama et al. · Cancer Discovery · 2014 · 842 citations · Full text
Medicine, Oncology, Pharmacology +15
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam Crystal, Alice T. Shaw, Lecia V. Sequist et al. · Science · 2014 · 733 citations
Medicine, Oncology, Pharmacology +17
1–5 of 73